Merck And RidgebackBio To Reap Huge Profits On New Covid Pill Paid For By US Taxpayers?
According to a recent report in The Intercept, Merck’s total costs to produce a five-day course of molnupiravir – the new drug to be approved for early treatment of Covid-19 – is $17.74. However, they have charged the U.S. government $712 for that treatment....